Plant-Based Vaccines Market Report 2026

The plant-based vaccines market size has grown rapidly in recent years. It will grow from $1.81 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to limited cold chain infrastructure in developing regions, high cost of conventional vaccine production, increasing prevalence of zoonotic diseases, early academic research in plant molecular farming, government support for alternative biologics.

The plant-based vaccines market size is expected to see rapid growth in the next few years. It will grow to $3.06 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to rising demand for scalable vaccine platforms, growth in pandemic preparedness programs, increasing investment in plant biotechnology startups, demand for cost-effective veterinary vaccines, regulatory progress for novel vaccine platforms. Major trends in the forecast period include expansion of recombinant antigen expression in plants, rising adoption of plant-based platforms for veterinary vaccines, increased focus on oral and edible vaccine development, growing public and private funding for alternative vaccine platforms, advancements in downstream processing and purification technologies.

The high prevalence of infectious diseases is anticipated to drive the growth of the plant-based vaccines market in the coming years. Infectious diseases are conditions caused by pathogenic microorganisms such as bacteria, viruses, or parasites, which can spread through direct or indirect transmission and pose substantial global health risks. The rise in infectious disease cases is influenced by factors including increased global travel, urban overcrowding, and reduced immunity in certain population groups. Plant-based vaccines provide innovative platforms that can be rapidly scaled and adapted to respond effectively to these growing health challenges. For instance, in March 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, reflecting a rise of 1,295 cases. Therefore, the high prevalence of infectious diseases is contributing to the expansion of the plant-based vaccines market.

Leading companies operating in the plant-based vaccines market are pursuing strategic manufacturing collaborations to expand clinical-stage production capacity and accelerate the development of next-generation virus-like particle (VLP)-based vaccines. These manufacturing partnerships are designed to improve downstream processing efficiency, ensure compliance with good manufacturing practices (GMP), and support a smooth transition from early research stages to clinical development. For example, in December 2024, Aramis Biotechnologies Inc., a Canada-based company focused on plant-based biomanufacturing of innovative vaccines, entered into a partnership with Biodextris Inc., a Canada-based contract development and manufacturing organization specializing in cGMP complex biologics, to support Phase 1 and Phase 2 clinical trials. Under this collaboration, Biodextris will handle purification, formulation, and fill-finish operations for plant-derived VLP vaccine candidates, enabling faster scale-up, improved production quality, and enhanced readiness for advanced clinical evaluation.

In December 2023, Aramis Biotechnologies, a Canada-based biotechnology company, acquired key assets from Medicago for an undisclosed amount. Through this acquisition, Aramis seeks to strengthen its position in the plant-based vaccines market by utilizing Medicago’s virus-like particle platform to develop next-generation influenza vaccines and therapeutics. The transaction also preserves high-speed domestic manufacturing capabilities, supporting sustainable biomanufacturing and enhanced pandemic preparedness. Medicago is a Canada-based biotechnology company that develops vaccines using plant-based technology.

Major companies operating in the plant-based vaccines market are British American Tobacco PLC, Medicago Inc., Creative Biolabs Inc., Fraunhofer USA Inc., Biodextris Inc., Avesthagen Limited, Calyxt Inc., Mapp Biopharmaceutical Inc., Kentucky BioProcessing Inc., Planet Biotechnology Inc., Icon Genetics GmbH, PlantForm Corporation, LenioBio GmbH, iBio Inc., Lumen Bioscience Inc., Baiya Phytopharm Co. Ltd., Greenovation Biotech GmbH, Pevion Biotech AG, Zyus Life Sciences Inc., Agenus Inc.

North America was the largest region in the plant-based vaccines market in 2025. The regions covered in the plant-based vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plant-based vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the plant-based vaccines market by increasing costs for imported bioprocessing equipment, reagents, and genetically engineered plant materials used in recombinant vaccine production. These impacts are most evident across viral and bacterial vaccine segments and in regions reliant on cross-border supply chains such as North America, Europe, and parts of Asia-Pacific. Higher tariffs have led manufacturers to reassess sourcing strategies and delay capacity expansion in some cases. However, tariffs have also encouraged localized manufacturing, domestic cultivation of plant sources, and regional R&D investments, supporting long-term supply chain resilience and innovation.

The plant-based vaccines market research report is one of a series of new reports that provides plant-based vaccines market statistics, including plant-based vaccines industry global market size, regional shares, competitors with a plant-based vaccines market share, detailed plant-based vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the plant-based vaccines industry. This plant-based vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plant-based vaccines are recombinant vaccines in which antigens targeting specific infections are expressed in selected plant species. These vaccines have the potential to effectively prevent or treat a wide range of human and animal diseases.

The main types of plant-based vaccines include bacterial vaccines, viral vaccines, parasite vaccines, and others. Bacterial vaccines are preparations made from inactivated or weakened bacteria that are used as active immunizing agents. These vaccines are produced using various plant sources such as tobacco plants, maize, potatoes, and others, and are applied in areas including influenza, Zika virus, Ebola virus, poultry diseases, and other applications.

The plant-based vaccines market consists of sales of cholera vaccines and norovirus vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.